Tibet Aim Pharm. Inc. announcement: The company's wholly-owned subsidiary TAPI Healthcare Inc. plans to reduce its capital and participate in the shareholding of Pier 88 Health Limited, with a total repurchase price of 6.4912 million US dollars.
易明医药：子公司TAPI拟649.12万美元减资开曼彼爱
Tibet Aim Pharm. Inc.: Its subsidiary TAPI plans to reduce its capital by 6.4912 million US dollars and establish a Cayman BPI.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated